Vaccination of HIV-1 Infected Patients With ex-Vivo Generated Interferon-alpha Dendritic Cells Loaded With HIV-1 Lipopeptides and Activated With Lipopolysaccharide in Addition to Antiretroviral Treatment: Exploratory Phase I Study - (DALIA Trial).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HIV vaccine (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms DALIA

Most Recent Events

12 Jun 2017 Biomarkers information updated
08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
21 Feb 2012 Planned end date changed from 1 May 2010 to 1 May 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight